Skip to main content

ADx Healthcare to Launch Alzheimer's Polygenic Risk Test Through Japanese Clinic

NEW YORK – Alzheimer's disease testing firm ADx Healthcare said today that it has partnered with Osaka, Japan-based Nakanoshima Clinic and Ixlayer, a San Francisco health IT company, to launch a polygenic-risk score for early detection of Alzheimer’s disease in Japan.

The test, called GenoRisk, assays 32 genetic loci, with results analyzed and interpreted by ADx Healthcare's medical team. According to the firm's CEO Steve Booth, the panel included both risk-associated and protective genes that influence Alzheimer's disease risk.

ADx has previously worked with Ixlayer to provide software and other services to create patient reports for direct-to-consumer Alzheimer's testing — in this case limited to the APOE gene — through consumer genomics firm Helix.

For the new polygenic risk test in Japan, ADx said that IxLayer's contribution will help ensure customers have access to clinicians throughout the process as well as educational information tailored to a patient's specific results.

"We have done extensive patient research here in the US on how to deliver this type of information to patients and are excited to tailor our product to patients located in Japan," IxLayer CEO Pouria Sanae said in a statement.

The Nakanoshima health center, which will market the test to its patients, is one of five clinics owned by the Shinyukai group, headquartered in Kyoto, Japan.